Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 22.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 56,288 shares of the medical research company’s stock after buying an additional 10,270 shares during the quarter. Janus Henderson Group PLC’s holdings in Charles River Laboratories International were worth $10,390,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Pinnacle Bancorp Inc. increased its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. Optiver Holding B.V. acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at about $37,000. GeoWealth Management LLC increased its holdings in shares of Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at about $48,000. Finally, Tortoise Investment Management LLC increased its holdings in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 115 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, COO Birgit Girshick bought 1,514 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph W. Laplume sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares in the company, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,040 shares of company stock worth $807,407. 1.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of research reports. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their price objective for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. UBS Group reissued a “neutral” rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Robert W. Baird increased their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the company a “neutral” rating in a report on Thursday, May 8th. Finally, Morgan Stanley lowered their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and a consensus target price of $172.31.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $141.00 on Friday. The company has a market capitalization of $6.93 billion, a P/E ratio of 940.00, a P/E/G ratio of 4.54 and a beta of 1.50. The business’s 50 day moving average is $135.43 and its two-hundred day moving average is $164.97. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.27 earnings per share. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).